PolyPid Ltd. (PYPD)

4.4900 +0.1500 (+3.46%) 收市：04:00PM EDT

PolyPid Ltd.

18 Hasivim Street
Petah Tikva 4959376
Israel
972 7 4719 5700
https://www.polypid.com

版塊: Healthcare
行業: Biotechnology
全職員工: 59

高階主管

名稱	頭銜	支付	行使價	出生年份
Ms. Dikla Czaczkes Akselbrad	CEO & Director	347.88k	無	1973
Mr. Jonny Missulawin	Chief Financial Officer	186.96k	無	1987
Ms. Dalit Hazan	Executive Vice President of R&D and Clinical & Regulatory Affairs	272.38k	無	1971
Mr. Ori Warshavsky	Chief Operating Officer - US	340.89k	無	1978
Ms. Maria Rubin	Vice President of Operations	無	無	無
Mr. Tal Vilnai	General Counsel & Corporate Secretary	無	無	無
Ms. Rivi Lev-ari	Vice President of Human Resource	無	無	無
Dr. Jean-Marc Hagai Pharm.D.	Chief Commercial Officer	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.

公司管治

截至 無 止，PolyPid Ltd. 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。